| Half-life | 10 hours |
| Tmax | 1 h |
| Bioavailability | 98 % (approx) |
| Protein Binding | 98 % |
| Volume of Distribution | 0.2 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Shorter half-life than warfarin; INR unstable in non-compliant patients; rapid offset. |
Severity: Severe
Adverse Effects:
Bleeding (GI/intracranial), skin necrosis (rare in protein C/S deficiency), INR variability, teratogenicity
Contraindications:
Pregnancy, active bleeding, severe hepatic impairment, uncontrolled hypertension
Precautions:
Requires frequent INR monitoring; avoid sudden dietary vitamin K changes; more sensitive to missed doses due to shorter half-life